Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI
Cancers · 07.09.2023 · 15 (18) · 4453
DOI: 10.3390/cancers15184453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 07.09.2023. Verfasst von Laiz Laura de Godoy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose: The isocitrate dehydrogenase (IDH) mutation has become one of the most important prognostic biomarkers in glioma management, indicating better treatment response and prognosis. IDH mutations confer neomorphic activity leading to the conversion of alpha-ketoglutarate (α-KG) to 2-hydroxyglutarate (2HG). The purpose of this study was to investigate the clinical potential of proton MR spectroscopy (1H-MRS) in identifying IDH-mutant gliomas by detecting characteristic resonances of 2HG and its complex interplay with other clinically relevant metabolites. Materials and Methods: Thirty-two patients with suspected infiltrative glioma underwent a single-voxel (SVS, n = 17) and/or single-slice-multivoxel (1H-MRSI, n = 15) proton MR spectroscopy (1H-MRS) sequence with an optimized echo-time (97 ms) on 3T-MRI. Spectroscopy data were analyzed using the linear combination (LC) model. Cramér–Rao lower bound (CRLB) values of
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Neuroradiology, Singapore General Hospital, Singapore 169609, Singapore.
- Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
- Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
- Glioblastoma Translational Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19014, USA.
ORCID-Profile: Sanjeev Chawla, Suyash Mohan
Zitieren
APA
de Godoy, L. L., Lim, K. C., Rajan, A., Verma, G., Hanaoka, M., O'Rourke, D. M., Lee, J. Y. K., Desai, A., Chawla, S., & Mohan, S. (2023). Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI. Cancers, 15(18), 4453. https://doi.org/10.3390/cancers15184453
Vancouver
de Godoy LL, Lim KC, Rajan A, Verma G, Hanaoka M, O'Rourke DM, et al. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI. Cancers. 2023;15(18):4453. doi:10.3390/cancers15184453
BibTeX
@article{deGodoy2023,
author = {de Godoy, Laiz Laura and Lim, Kheng Choon and Rajan, Archith and Verma, Gaurav and Hanaoka, Mauro and O'Rourke, Donald M and Lee, John Y K and Desai, Arati and Chawla, Sanjeev and Mohan, Suyash},
title = {Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI},
journal = {Cancers},
year = {2023},
volume = {15},
number = {18},
pages = {4453},
doi = {10.3390/cancers15184453}
}
EUVIMED